I guess the obvious question is whether there is room for both (or more), or whether Propellor and/or maybe some others already have the market sewn up and we are too late to the party?
Or is it the case that Adherium will be used for AZ drugs, Propellor will be used for BI and GSK drugs, and thus the market is already neatly segregated.
of interest, page-19
Add ADR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.001(5.88%) |
Mkt cap ! $7.021M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.8¢ | 1.6¢ | $31.41K | 1.880M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 2237174 | 1.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 257503 | 5 |
View Market Depth
| Last trade - 16.10pm 08/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.7¢ |
Change
0.001 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 1.7¢ | 1.7¢ | 1.7¢ | 256435 | ||
| Last updated 15.55pm 08/05/2024 ? | |||||
| ADR (ASX) Chart |